Article
Antiandrogen/castration may reduce death risk by 20%
New Orleans--Bicalutamide (Casodex), 50 mg, plus castration leads to an estimated 20% reduction in risk of prostate cancer death versus castration alone, according to results of a historical data analysis presented at the annual of the American Society of Clinical Oncology meeting here.
Related Videos
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
The MOA of TLX250
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
The ZIRCON Trial
Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
Bladder-Sparing Breakthroughs: Novel FDA-Approved Treatment Options for NMIBC
Expert Discussion on BCG-Unresponsive NMIBC
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
Related Content
